Notably, the levels of SOCS3 are correlated with the deposition of Aβ (Walker et al., 2015; Cianciulli et al., 2017; Iwahara et al., 2017), suggesting that SOCS3 might be a novel target that regulates insulin signaling in the brains of AD patients. The gene discussed is SOCS3; the disease is Alzheimer disease.